Back to results
US 2022/0017587 A1Published application
Dual cytokine fusion proteins comprising il-10
AssigneeDeka Biosciences, Inc.
InventorJohn MUMM
Life of this patent
Estimating the term…
Abstract
The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
Claims9
A dual cytokine fusion protein of formula (I)
- NH2-(IL-10)-(X1)-(Zn)-(X2)—(IL-10)-COOH (Formula I);
- wherein
- “IL-10” is a monomer of SEQ ID No:
- 16;
- “X1” is a variable light (VL) or variable heavy (VH) chain region comprising three complementarity determining regions (CDRs) that bind to epidermal growth factor receptor (EGFR);
- “X2” is a VH or VL region comprising three CDRs that bind to EGFR;
- wherein when X1 is a VL, X2 is a VH and when X1 is a VH, X2 is a VL, and wherein the CDRs are obtained from an anti-EGFR monoclonal antibody and wherein X1 and X2 together form a single chain variable fragment (scFv);
- “Z” is IL-2;
- and
- “n” is an integer of 1.
7 more elements
2-3. (canceled)
5-6. (canceled)
8-21. (canceled)
Dependencies are inferred from the claim text.